Enanta Pharmaceuticals Inc(ENTA) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Current Price

$48.50

RSI

28.619

Beta:

0.400441

February 09, 2021
8.7M
-15.1M

-39.618 %
-42.721 %
-177.755 %
-923.259 %

$122,622,000
$205,197,000
$206,566,000
$102,814,000
$88,268,000
$160,880,000
-67.341 %
-0.667 %
100.912 %
16.479 %
-82.263 %

$-35,019,000
$45,557,000
$93,121,000
$26,947,000
$32,560,000
$125,455,000
-230.092 %
-104.405 %
245.571 %
-20.830 %
-285.304 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.